A pivotal phase II clinical study of cemiplimab, an investigational human antibody targeting PD-1, demonstrated an overall response rate of 46.3% in 82 patients with advanced cutaneous squamous cell carcinoma.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe